NIA Study Confirms Protandim Nrf2 Synergizer Extends Life
As part of the NIA ITP federally-funded program that examines treatments with the "potential to extend lifespan and delay disease and dysfunction," and thereby extend lifespan, researchers provided the supplement Protandim®, the Nrf2 Synergizer® to male mice in a rigorous and carefully controlled study. The result: Protandim was proven to "significantly increase the lifespan of male mice, with a 7 percent increase in median survival." The findings on female mice were less dramatically conclusive, showing an increase in lifespan of 3 percent.
Since the NIA ITP program's inception in 1999, Protandim is the only nutritional supplement tested that has been proven to increase the median survival in mice, thus delaying the aging process.
Protandim was chosen for testing based on positive indications on its ability to suppress tumor-promoting oxidative stress, cell proliferation and inflammation, and the ability to protect the heart from oxidative stress and fibrosis in studies published prior to 2010. Some of the other recognized nutritional substances tested included fish oil, curcumin, green tea and resveratrol. None of these individual ingredients were shown to increase the lifespan of mice.
"We are extremely excited about these results from the NIA ITP study and are enthusiastic about the continued advancement of the research and findings that demonstrate Protandim's veracity and effectiveness in additional studies to come," said
For more information about the Protandim results in the NIA's study, readers can click here or visit: http://onlinelibrary.wiley.com/doi/10.1111/acel.12496/abstract.
About
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future growth and distributor success. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current
expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements
to reflect events or circumstances after the date of this document, except as required by law.
Company Relations Contact:John Genna (801) 432-9172 Vice President of Communications & Corporate Partnerships Investor Relations Contacts:Cindy England (801) 432-9036 Director of Investor Relations -Or-Scott VanWinkle (617) 956-6736 Managing Director, ICR
News Provided by Acquire Media